RAFAEL HOLDINGS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
RAFAEL HOLDINGS, INC. (RFL) reported Cash and Cash Equivalents, Period Increase (Decrease) of $64.53 million for the 3-month period ending 2021-10-31, per its 10-Q/A filed 2022-02-28.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2022-02-28
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-10-31 was $64.53M, a 6195.90% increase year-over-year.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-07-31 was $8.18M.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-04-30 was -$1.41M.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2021-01-31 was -$1.15M.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2021 was $6.65M.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2020 was -$5.82M.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$3.78M, a 193.38% decline from fiscal 2018.
- RAFAEL HOLDINGS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $4.05M, a 57.02% decline from fiscal 2017.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2021-10-31 | $64.53M 10-Q/A · filed 2022-02-28 | $72.71M derived: sum of 2 quarters · filed 2022-02-28 | $71.30M derived: sum of 3 quarters · filed 2022-02-28 | $70.16M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-07-31 | $8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | $6.77M derived: sum of 2 quarters · filed 2021-10-18 | $5.62M derived: sum of 3 quarters · filed 2021-10-18 | $6.65M 10-K · filed 2021-10-18 |
| 2021-04-30 | -$1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | -$2.55M derived: sum of 2 quarters · filed 2021-06-14 | -$1.53M 10-Q · filed 2021-06-14 | -$3.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-01-31 | -$1.15M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2021-03-17 | -$120.00K 10-Q · filed 2021-03-17 | -$2.34M derived: sum of 3 quarters · filed 2022-02-28 | -$3.44M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-10-31 | $1.02M 10-Q/A · filed 2022-02-28 | -$1.20M derived: sum of 2 quarters · filed 2022-02-28 | -$2.29M derived: sum of 3 quarters · filed 2022-02-28 | -$3.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-07-31 | -$2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | -$3.32M derived: sum of 2 quarters · filed 2021-10-18 | -$4.57M derived: sum of 3 quarters · filed 2021-10-18 | -$5.82M 10-K · filed 2021-10-18 |
| 2020-04-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | -$2.34M derived: sum of 2 quarters · filed 2021-06-14 | -$3.59M 10-Q · filed 2021-06-14 | -$4.54M derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-01-31 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | -$2.50M 10-Q · filed 2021-03-17 | -$3.45M derived: sum of 3 quarters · filed 2021-03-17 | -$5.25M derived: sum of 4 quarters · filed 2021-03-17 |
| 2019-10-31 | -$1.25M 10-Q · filed 2020-12-15 | -$2.20M derived: sum of 2 quarters · filed 2020-12-15 | -$4.00M derived: sum of 3 quarters · filed 2020-12-15 | $685.00K derived: sum of 4 quarters · filed 2020-12-15 |
| 2019-07-31 | -$945.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | -$2.75M derived: sum of 2 quarters · filed 2020-10-29 | $1.94M derived: sum of 3 quarters · filed 2020-10-29 | -$3.78M 10-K · filed 2020-10-29 |
| 2019-04-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-09 | $2.88M derived: sum of 2 quarters · filed 2020-06-09 | -$2.83M 10-Q · filed 2020-06-09 | $2.36M derived: sum of 4 quarters · filed 2020-06-09 |
| 2019-01-31 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-03-05 | -$1.03M 10-Q · filed 2020-03-05 | $4.16M derived: sum of 3 quarters · filed 2020-03-05 | $2.76M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-10-31 | -$5.72M 10-Q · filed 2019-12-09 | -$519.00K derived: sum of 2 quarters · filed 2019-12-09 | -$1.92M derived: sum of 3 quarters · filed 2019-12-09 | -$1.43M derived: sum of 4 quarters · filed 2019-12-09 |
| 2018-07-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-04 | $3.79M derived: sum of 2 quarters · filed 2019-10-04 | $4.28M derived: sum of 3 quarters · filed 2019-10-04 | $4.05M 10-K · filed 2019-10-04 |
| 2018-04-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-06-05 | -$914.00K derived: sum of 2 quarters · filed 2019-06-05 | -$1.15M 10-Q · filed 2019-06-05 | -$1.12M derived: sum of 4 quarters · filed 2019-06-05 |
| 2018-01-31 | $489.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-12 | $252.00K 10-Q · filed 2019-03-12 | $279.00K derived: sum of 3 quarters · filed 2019-03-12 | $147.00K derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-10-31 | -$237.00K 10-Q · filed 2018-12-10 | -$210.00K derived: sum of 2 quarters · filed 2018-12-10 | -$342.00K derived: sum of 3 quarters · filed 2018-12-10 | |
| 2017-07-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15 | -$105.00K derived: sum of 2 quarters · filed 2018-10-15 | $9.42M 10-K · filed 2018-10-15 | |
| 2017-04-30 | -$132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-06-11 | $9.39M 10-Q · filed 2018-06-11 | ||
| 2017-01-31 | $9.52M 10-Q · filed 2018-03-12 | |||
| 2016-07-31 | -$3.31M 10-K · filed 2018-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |